Eli Lilly: Oral GLP-1RA orforglipron outperforms oral semaglutide in head-to-head studies

On September 17th local time, Eli Lilly announced positive top-line results from the ACHIEVE-3 study, which is an open-label, randomized phase 3 clinical trial assessing the safety and efficacy of orforglipron compared to oral semaglutide in 1,698 adult participants with type 2 diabetes who had inadequate blood sugar control on metformin treatment. The study lasted 52 weeks and compared the results of orforglipron with oral semaglutide in terms of blood sugar control and weight loss across four active treatment groups. At 52 weeks, all dose groups of orforglipron achieved the primary endpoint and all key secondary endpoints, showing superior improvements in hemoglobin A1c and weight compared to oral semaglutide